Merck Looking To Phase III Trials As Pivotal Proving Ground For HCV Combo
This article was originally published in The Pink Sheet Daily
After disappointing Phase II results presented at AASLD, the pressure is on Merck’s four Phase III trials of the grazoprevir/elbasvir fixed-dose combination, including a study in patients with chronic kidney disease, where the doublet may offer a safety advantage.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.